Article

Transitioning From Vial To Prefilled Syringe: How Formulation Development Affects Manufacturing

Source: Catalent

By Natasha Van Rutten, Product Development Director, Catalent Biologics

iStock-1283232421-syringe-glove-hand-injection

Due to advances in technology and increased development of parenteral drugs, one of the fastest growing choices for drug delivery in the pharmaceutical industry is the prefilled syringe (PFS).1 Not only can PFSs help cut manufacturing and product costs for pharmaceutical companies, but they also offer significant benefits to the physician and patient. However, before taking advantage of these benefits, it is important to understand how formulation development for a PFS affects manufacturing. Doing so can drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: